Anpac Bio-Medical Introduces 'Game Changing' Cancer Screening Tech at American Society of Clinical Oncology Meeting - Chicago 5/29 - 6/2

SACRAMENTO, Calif., May 29, 2015 /PRNewswire/ -- Anpac Bio-Medical Science Co., Ltd., Chief Executive Officer and Scientist Dr. Chris Yu and the Anpac research team are introducing what the 2015 Nobel Prize Laureate Summit on Biomedical Science (NPLS) organizers published as, "game changing" and "breakthrough" early cancer detection technology research results at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29 – June 2, 2015.

An accomplished inventor with over 200 patent applications (100 related to leading-edge cancer research/diagnostics), and ASCO member, Dr. Yu and team will be sharing with ASCO Annual Meeting participants Anpac's "Cancer Differentiation Analysis" (CDA) technology results from four key research studies: Esophageal Cancer (Abstract #: 149495); Digestive System/Stomach Cancer (Abstract #152163); Hepatocellular Carcinoma (Abstract # 148693); and Lung Cancer (Abstract #12587): http://abstracts.asco.org/156S/search.php?zoom_sort=0&zoom_query=anpac+bio-medical&zoom_per_page=10&zoom_and=0. Among the Anpac ASCO Abstract highlights: the screening of non-small cell lung cancer and esophageal cancers in particular, demonstrated dramatic improvement in terms of identification sensitivity and specificity on Stage 1 tumors,  over the existing, traditional diagnostic technologies.

Overall, the research results reveal that Anpac's CDA effectively reinvents cancer screening and early cancer detection, through simple, standard, non-invasive blood tests – known as "Blood Biopsies" – and Anpac CDA medical devices.

Anpac's CDA technology essentially executes for patients and doctors "Blood Biopsies", which comprehensive research indicates quickly, efficiently, and significantly improves cancer detection sensitivity and specificity – without producing any side effects in patients.

In other words, Anpac's CDA diagnostics can detect and identify early signals of threatening cancer – and the type of cancer (location in the body) – often before the threat becomes or grows into tumors.

Comprehensive research validity data from nearly 20,000 cases indicate Anpac's CDA diagnostics far exceed existing or competing technologies – revealing a sensitivity and specificity rate range of 70%-85% for over ten different types of cancer, with the ability of early stage detection for most of them.

Dr. Yu will be introducing and describing the specific results from four separate CDA studies to oncology professionals worldwide, and other interested parties and media, at the ASCO Annual meeting May 29 – June 2, 2015. The 51st ASCO Annual Meeting in Chicago will attract more than 25,000 oncology professionals from around the world.

For further information: Anpac Bio-Medical Science Company, Ltd.: http://www.anpac.cn/IndexEn.htm; and ASCO: http://abstracts.asco.org/156/IndexView_156.html.

PDF - http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/0-Anpac-Bio-Medical-Science-Co-Ltd---AP-15-Abstract-ASCO-Hepatocellular-Carcinoma.pdf

PDF - http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/0-Anpac-Bio-Medical-Science-Co-Ltd---AP-15-Abstract-ASCO-Digestive-System.pdf

PDF - http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/0-Anpac-Bio-Medical-Science-Co-Ltd---AP-15-Abstract-ASCO-Lung-Cancer.pdf

PDF - http://origin-qps.onstreammedia.com/origin/multivu_archive/ENR/0-Anpac-Bio-Medical-Science-Co-Ltd---AP-15-Abstract-ASCO-Esophageal-Cancer.pdf

SOURCE Anpac Bio-Medical Science Company, Ltd.

Related Links

http://www.anpac.cn